Tag Archive for: Series A

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline

Series A financing led by Pfizer Ventures with new investors Columbus Venture Partners and British Patient Capital which join founding investor Advent Life Sciences and seed investor Epidarex Capital Goal to advance proprietary discovery platform and progress pipeline of assets addressing challenging cancer targets into the clinic Southampton, UK, 27 February 2023 – Curve Therapeutics […]

AstronauTx closes £48 million ($61 million) Series A financing to create new treatments for Alzheimer’s disease

AstronauTx is a biotech company developing new treatments for neurodegenerative conditions based on amplifying the brain’s own physiological protective mechanisms Proceeds of the financing will be used to advance a portfolio of programmes and take the lead molecule into clinical trials The syndicate, led by the Novartis Venture Fund, also includes MPM Capital, Brandon Capital, […]

Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform

Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, […]

Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers

Oversubscribed financing co-led by HealthCap and EQT Life Sciences (formerly LSP); joined by Pureos Bioventures Developing novel drugs for systemic targeted radiation therapy (STRT) Proceeds will be used to advance lead radiopharmaceutical product, satoreotide, for the treatment of neuroendocrine cancers and certain other aggressive, hard-to-treat cancers Led by industry veteran Manfred Rüdiger as CEO, and world-renowned […]